Loading organizations...
TenSixteen Bio develops precision therapeutics targeting somatic mosaicism, particularly clonal hematopoiesis of indeterminate potential (CHIP). The company analyzes DNA changes accumulating in cells over a lifetime, translating these genetic insights into treatments. This approach aims to intercept and modulate complex and age-related disease progression.
Mark Chao, MD, PhD, co-founded TenSixteen Bio and serves as Chief Executive Officer. Launched in 2020 from Foresite Labs, the company was established based on Dr. Chao’s prior experience and the insight that somatic mosaicism critically influences disease development. Scientific advisors, including Alex Bick, Benjamin Ebert, and Siddhartha Jaiswal, reinforce this understanding.
TenSixteen Bio targets patients confronting complex and age-related diseases, aiming to transform treatment paradigms. Its vision is to advance precision medicine by profoundly understanding and therapeutically manipulating somatic genomic alterations. This seeks to prevent and treat conditions early, ultimately improving outcomes and extending healthy lifespans.
TenSixteen Bio has raised $40.0M across 1 funding round.
TenSixteen Bio has raised $40.0M in total across 1 funding round.
TenSixteen Bio has raised $40.0M in total across 1 funding round.
TenSixteen Bio's investors include ARCH Venture Partners, Foresite Capital, GV, Mithril Capital Management, Polaris Partners, RA Capital.
TenSixteen Bio has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series A in January 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2022 | $40M Series A | — | ARCH Venture Partners, Foresite Capital, GV, Mithril Capital Management, Polaris Partners, RA Capital | Announced |
TenSixteen Bio is a biotechnology company developing novel therapeutics for age-related diseases by leveraging somatic mosaicism and clonal hematopoiesis (CHIP), the accumulation of DNA mutations in cells over time.[1][2] Headquartered in California and incubated by Foresite Labs, it builds genomic and clinical platforms to analyze these changes, enabling early detection and treatment of conditions like cancer and cardiovascular disease—the leading causes of morbidity and mortality in aging populations.[1][2][3] The company serves patients with complex diseases, solving the problem of late-stage interventions by targeting mutations early through precision medicine, with initial funding of $40M from Foresite Capital and GV in 2022 signaling strong growth momentum.[2]
TenSixteen Bio was founded in 2020 in California as the first company to apply CHIP and somatic mosaicism to drug discovery.[2][3] It was co-founded by CEO Mark Chao, a physician-scientist who previously co-founded Forty Seven (an immuno-oncology firm acquired by Gilead Sciences for $4.9B), served as VP of Oncology at Gilead, and was a Clinical Instructor at Stanford University.[2] The idea emerged from Chao's clinical experience observing the limitations of end-stage disease treatments, prompting a shift toward earlier intervention via somatic mutations in blood and tissues.[2] Incubated by Foresite Labs, the company launched in January 2022 with $40M in funding from Foresite Capital and GV, marking its early traction in redefining precision medicine.[1][2]
TenSixteen Bio rides the trend of precision medicine and aging biology, capitalizing on advances in genomics to address somatic mutations that drive major killers like cancer and heart disease.[1][2] Timing is ideal amid rising U.S. aging populations and limitations of current therapies, where CHIP offers a new lens for proactive interventions.[2] Market forces favoring it include booming biotech investment in data platforms and the push for early detection, amplified by post-pandemic focus on chronic diseases.[2] It influences the ecosystem by pioneering CHIP applications, potentially inspiring similar somatic-focused startups and accelerating therapeutic innovation across biotech.
TenSixteen Bio is poised to advance its platform toward clinical candidates targeting CHIP-driven diseases, with pipeline expansion into broader age-related conditions likely next.[1][2] Trends like AI-enhanced genomics and multimodal data integration will shape its trajectory, enhancing mutation analysis speed and accuracy. Its influence may evolve by establishing CHIP as a standard in precision oncology and cardiology, building on founder expertise and VC momentum to deliver paradigm-shifting therapies—echoing its launch as a trailblazer in somatic biology.[2]
